Bioreactors for cell therapies: Current status and future advances

Shannon Eaker, Eytan Abraham, Julie Allickson, Thomas A. Brieva, Dolores Baksh, Thomas R.J. Heathman, Biren Mistry, Nan Zhang

Research output: Contribution to journalReview articlepeer-review

Abstract

The use of bioreactors in cell therapy applications is on the rise, as clinical trials and commercialization of cell therapy–based products are moving to the forefront of treatment opportunities. This review focuses on the considerations and benefits of using bioreactors for cell therapy manufacturing, with an emphasis on autologous versus allogenic, scalability, tissue engineering, automation and comparability and consistency in the final product. Evaluation and choice of the right bioreactor for any given process and indication is paramount when moving into scalable platforms and processes that can support the cell therapy industry's needs.

Original languageEnglish (US)
Pages (from-to)9-18
Number of pages10
JournalCytotherapy
Volume19
Issue number1
DOIs
StatePublished - Jan 1 2017

Keywords

  • allogeneic
  • autologous
  • bioreactor
  • cell culture
  • cell therapy
  • scale-out
  • scale-up
  • stem cell
  • tissue engineering

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Genetics(clinical)
  • Cell Biology
  • Cancer Research
  • Transplantation

Fingerprint

Dive into the research topics of 'Bioreactors for cell therapies: Current status and future advances'. Together they form a unique fingerprint.

Cite this